Literature DB >> 32530398

In vivo and in vitro cross-reactivity to fondaparinux in a stroke patient with IgG-PF4/heparin antibody-negative delayed-onset heparin-induced thrombocytopenia.

Ivan Krečak1, Gordana Tomac2, Jakša Škugor3, Velka Gverić-Krečak1, Dražen Pulanić4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32530398      PMCID： PMC7375882          DOI： 10.2450/2020.0037-20

Source DB:  PubMed          Journal:  Blood Transfus        ISSN： 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  13 in total

Review 1.  Laboratory diagnosis of heparin-induced thrombocytopenia and monitoring of alternative anticoagulants.

Authors:  Albrecht Leo; Susanne Winteroll
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

2.  Heparin-induced thrombocytopenia associated with fondaparinux.

Authors:  Theodore E Warkentin; Brian T Maurer; Richard H Aster
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

3.  Severe and persistent heparin-induced thrombocytopenia despite fondaparinux treatment.

Authors:  Ariella Tvito; Tamam Bakchoul; Jacob M Rowe; Andreas Greinacher; Chezi Ganzel
Journal:  Am J Hematol       Date:  2015-02-27       Impact factor: 10.047

Review 4.  Autoimmune manifestations associated with myelodysplastic syndromes.

Authors:  Eric Grignano; Vincent Jachiet; Pierre Fenaux; Lionel Ades; Olivier Fain; Arsène Mekinian
Journal:  Ann Hematol       Date:  2018-08-08       Impact factor: 3.673

5.  Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorder.

Authors:  Theodore E Warkentin; Paul A Basciano; Jared Knopman; Richard A Bernstein
Journal:  Blood       Date:  2014-03-27       Impact factor: 22.113

Review 6.  Fondaparinux: does it cause HIT? Can it treat HIT?

Authors:  Theodore E Warkentin
Journal:  Expert Rev Hematol       Date:  2010-10       Impact factor: 2.929

7.  Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.

Authors:  Pavan K Bendapudi; Shelley Hurwitz; Ashley Fry; Marisa B Marques; Stephen W Waldo; Ang Li; Lova Sun; Vivek Upadhyay; Ayad Hamdan; Andrew M Brunner; John M Gansner; Srinivas Viswanathan; Richard M Kaufman; Lynne Uhl; Christopher P Stowell; Walter H Dzik; Robert S Makar
Journal:  Lancet Haematol       Date:  2017-03-02       Impact factor: 18.959

8.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia.

Authors:  Adam Cuker; Gowthami M Arepally; Beng H Chong; Douglas B Cines; Andreas Greinacher; Yves Gruel; Lori A Linkins; Stephen B Rodner; Sixten Selleng; Theodore E Warkentin; Ashleigh Wex; Reem A Mustafa; Rebecca L Morgan; Nancy Santesso
Journal:  Blood Adv       Date:  2018-11-27

9.  Stroke in patients with heparin-induced thrombocytopenia and the effect of argatroban therapy.

Authors:  Marian P LaMonte; Philip M Brown; Marcie J Hursting
Journal:  Crit Care Med       Date:  2004-04       Impact factor: 7.598

10.  Fondaparinux-related thrombocytopenia in a previous low-molecular-weight heparin (LMWH)-induced heparin-induced thrombocytopenia (HIT).

Authors:  Eugenia Rota; Mario Bazzan; Giovanni Fantino
Journal:  Thromb Haemost       Date:  2008-04       Impact factor: 5.249
View more
  2 in total

Review 1.  Structural Features and PF4 Functions that Occur in Heparin-Induced Thrombocytopenia (HIT) Complicated by COVID-19.

Authors:  Zheng Cai; Mark I Greene; Zhiqiang Zhu; Hongtao Zhang
Journal:  Antibodies (Basel)       Date:  2020-10-10

Review 2.  Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia.

Authors:  Payel Datta; Fuming Zhang; Jonathan S Dordick; Robert J Linhardt
Journal:  Thromb J       Date:  2021-09-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.